News
Best treatment approach for early stage follicular lymphoma is unclear
Overall survival rates were similar with different treatment approaches, including watchful waiting.
News
Follow-up shows favorable results with acalabrutinib in MCL
The median duration of response exceeded 2 years with acalabrutinib monotherapy.
News
What is the optimal duration of maintenance in myeloma?
SAN FRANCISCO – Dr. Yvonne A. Efebera and Dr. Nina Shah debate whether patients with multiple myeloma should receive maintenance until progression...
News
Hypoxia-related discoveries net Nobel Prize
A trio of physician scientists have won the Nobel Prize for their work, which has implications for the treatment of anemia, cancer, and other...
Article
Cleveland Clinic taps Abraham as chair
Cleveland Clinic has a new chair of its hematology/medical oncology department, and researchers have won grants to study melanoma, head and neck...
News
Vaping-associated lung injury cases exceed 1,000
As of Oct. 1, there have been 1,080 confirmed and probable cases of lung injury associated with the use of e-cigarettes, or vaping.
News
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
News
Decoding biosimilar approvals
SAN FRANCISCO – Regulators must consider several factors when expanding the use of an approved biosimilar from one indication to another, based on...
News
Study finds no standard for treatment discontinuation in myeloma
BOSTON – Reasons for treatment discontinuation varied by regimen and line of therapy.
News
Immunotherapies under investigation in newly diagnosed B-ALL
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
News
Second-generation anti-BCMA CAR T-cell therapy shows promise in myeloma trial
BOSTON – None of the patients in the trial developed grade 3 or higher cytokine-release syndrome.
News
Subcutaneous and IV daratumumab combos appear comparable in myeloma
BOSTON – Response rates observed with subcutaneous daratumumab–based combinations in the PLEIADES trial were similar to rates observed with...
News
Quadruplet prolongs progression-free survival in newly diagnosed myeloma
BOSTON – Carfilzomib plus cyclophosphamide, lenalidomide, and dexamethasone significantly prolonged progression-free survival, compared with two...
News
Several factors may affect immune suppression discontinuation after HCT
Older age, advanced stage disease, having a mismatched unrelated donor, and receiving peripheral blood stem cells from an unrelated donor were...
Article
Multiple Myeloma Research Consortium, cancer centers add new leaders
The Multiple Myeloma Research Foundation, Fox Chase Cancer Center, the Oncology Institute of Hope and Innovation, and AAHPM Quarterly all made new...